---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-022408"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T11:10:27.609959+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vericel Q3 revenue up 7% to $34.5M; guides FY2021 revenue $158-$161M

## Summary
- Q3 total net revenue $34.5M (+7% YoY); MACI $23.9M, Epicel $9.8M (+48% YoY).
- Q3 net loss $4.9M ($0.11/sh) vs net income $3.6M in Q3 2020; non-GAAP adj. EBITDA $4.3M.
- FY2021 guidance: revenue $158-$161M (27-30% YoY growth); gross margin ~70%; adj. EBITDA margin ~22%.
- Cash and investments $119M, no debt; operating cash flow $3.6M in Q3.
- NexoBrid BLA resubmission expected mid-2022; MACI biopsies growth >30% expected in 2021.

## SEC filing metadata
- accession: 0001628280-21-022408
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828021022408/0001628280-21-022408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828021022408/vcel-20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-022408
- JSON: https://secwatch.observer/filing/0001628280-21-022408.json
- Plain text: https://secwatch.observer/filing/0001628280-21-022408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.